Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2625 of 2873 entries
View as:

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00294632 Org: User:
Start: 02/28/06 End: 02/29/16 Due: 02/28/17

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03187951 Org: User:
Start: 06/13/17 End: 12/31/26 Due: 12/31/27

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

Phase: N/A Priority: Normal
NCT ID: NCT04083378 Org: User:
Start: 01/10/20 End: 10/31/26 Due: 10/31/27

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

Phase: N/A Priority: Normal
NCT ID: NCT06561087 Org: User:
Start: 02/27/25 End: 05/30/29 Due: 05/30/30

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03471260 Org: User:
Start: 03/19/18 End: 09/30/25 Due: 09/30/26

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01321879 Org: User:
Start: 03/31/11 End: 12/31/16 Due: 12/31/17

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03683433 Org: User:
Start: 09/18/18 End: 09/20/25 Due: 09/20/26

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05961696 Org: User:
Start: 07/05/23 End: 10/03/23 Due: 10/03/24

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04432506 Org: User:
Start: 07/27/20 End: 05/28/24 Due: 05/28/25

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

Phase: N/A Priority: Normal
NCT ID: NCT00623974 Org: User:
Start: 05/31/08 End: 06/30/10 Due: 06/30/11

Personalized NK Cell Therapy in CBT

Phase: N/A Priority: Normal
NCT ID: NCT02727803 Org: User:
Start: 05/19/16 End: 05/31/27 Due: 05/31/28

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Phase: N/A Priority: Normal
NCT ID: NCT02636322 Org: User:
Start: 03/29/16 End: 10/24/22 Due: 10/24/23

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02253238 Org: User:
Start: 01/07/14 End: 04/30/27 Due: 04/30/28

Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT00543777 Org: User:
Start: 09/30/07 End: 01/13/20 Due: 01/13/21

Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03058926 Org: User:
Start: 01/19/17 End: 01/31/20 Due: 01/31/21

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03987386 Org: User:
Start: 05/30/19 End: 11/01/25 Due: 11/01/26

The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01193530 Org: User:
Start: 06/30/11 End: 03/31/16 Due: 03/31/17

CHESS: Human and Computer Mentors for Prostate Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00516256 Org: User:
Start: 07/03/07 End: 05/11/18 Due: 05/11/19

BATTLE Program: Sorafenib in Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00411671 Org: User:
Start: 11/30/06 End: 11/30/12 Due: 11/30/13

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03784677 Org: User:
Start: 07/29/19 End: 06/20/23 Due: 06/20/24

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02481297 Org: User:
Start: 06/23/15 End: 08/15/19 Due: 08/15/20

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05929612 Org: User:
Start: 07/28/23 End: 12/31/27 Due: 12/31/28

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

Phase: N/A Priority: Normal
NCT ID: NCT02464696 Org: User:
Start: 10/06/15 End: 10/01/26 Due: 10/01/27

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Phase: N/A Priority: Normal
NCT ID: NCT01746836 Org: User:
Start: 01/17/13 End: 12/31/30 Due: 12/31/31

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06318897 Org: User:
Start: 05/29/24 End: 09/30/27 Due: 09/30/28